Dr. Marcin A. Trojanowski, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 161
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Medical University of South Carolina College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MA license 268421
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boston Medical Center Boston, MA
Medical groups
- Evans Medical Foundation Inc (536 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 161
- Services billed
- 438
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 170 | 94 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 52 |
| Aspiration and/or injection of fluid from large joint | 53 | 37 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Boston, MA | 273 |
| Prednisone Other prescribers in Boston, MA | 187 |
| Celecoxib Other prescribers in Boston, MA | 179 |
| Mycophenolate Mofetil Other prescribers in Boston, MA | 143 |
| Hydroxychloroquine Sulfate Other prescribers in Boston, MA | 143 |
| Gabapentin Other prescribers in Boston, MA | 126 |
| Omeprazole Other prescribers in Boston, MA | 113 |
| Humira Pen (adalimumab) Other prescribers in Boston, MA | 96 |
| Diclofenac Sodium Other prescribers in Boston, MA | 71 |
| Tramadol Hcl Other prescribers in Boston, MA | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 21 payments worth $11,136 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,058 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,078 |
| Consulting Fee | $8,595 |
|---|---|
| Travel and Lodging | $1,467 |
| Food and Beverage | $1,074 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 1, 2025 | Consulting Fee | $5,775 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 7, 2025 | Consulting Fee | $2,820 |
| Novartis Pharmaceuticals Corporation May 3, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $277 |
| Novartis Pharmaceuticals Corporation Oct 24, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $263 |
| Novartis Pharmaceuticals Corporation Oct 24, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $262 |
| Novartis Pharmaceuticals Corporation May 3, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $181 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 1, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $140 |
| Novartis Pharmaceuticals Corporation May 3, 2025 | Travel and Lodging travel to Chicago, IL | $140 |
| Novartis Pharmaceuticals Corporation Oct 24, 2025 | Travel and Lodging travel to Chicago, IL | $117 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 7, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $86.54 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $36,986 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Amgen Inc. - P2b HZN-825-301 dcSSc BEACON
Amgen Inc. - A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participa…
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Amgen Inc. - A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microsc…
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-825 in Patients with Diffuse Cutaneous System…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.